Castle Biosciences Cuts 2026 Loss Estimate to $0.96 as Shares Rally 65%
Castle Biosciences’ 2026 loss per share estimate was reduced from $1.06 to $0.96 over the past 60 days, representing a 9.4% improvement. The stock has rallied 64.9% in the last six months as earnings projections have come in less negative than previously expected.
1. Estimate Revisions and Drivers
Over the past 60 days, analysts lowered Castle Biosciences’ 2026 loss per share estimate from $1.06 to $0.96, driven by stronger-than-expected revenue forecasts and operational efficiency gains in its tissue-based cancer diagnostics segment.
2. Stock Performance and Market Reaction
Shares of Castle Biosciences have climbed 64.9% over the past six months, reflecting investor optimism around improving margins, expanding test adoption, and a narrowing loss trajectory ahead of expected clinical data readouts.
Related News
NVO
Novo Nordisk Shares Slump 45% to 10x P/E as Pharma Fuels Danish GDP
NVO•
URBN
Urban Outfitters Q1 Sales Soar 11% to $1.5B, EPS Up 12%
URBN•
UXIN
Uxin to Launch 5,000-Vehicle Chongqing Superstore in 2026 Expansion Drive
UXIN•
CAAP
April Traffic Up 2.6% to 7.075M, Cargo Volume Rises 1.3%
CAAP•
GOOG
OpenAI Eyes Fall IPO After Lawsuit Win, Battling $900B Anthropic Rival
GOOG•
Sources
F